Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Gestational hypothyroxinemia induces ASD-like phenotypes in behavior, proinflammatory markers, and glutamatergic protein expression in mouse offspring of both sexes
Indexado
WoS WOS:001222504600001
Scopus SCOPUS_ID:85193067975
DOI 10.3389/FENDO.2024.1381180
Año 2024
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background The prevalence of autism spectrum disorder (ASD) has significantly risen in the past three decades, prompting researchers to explore the potential contributions of environmental factors during pregnancy to ASD development. One such factor of interest is gestational hypothyroxinemia (HTX), a frequent condition in pregnancy associated with cognitive impairments in the offspring. While retrospective human studies have linked gestational HTX to autistic traits, the cellular and molecular mechanisms underlying the development of ASD-like phenotypes remain poorly understood. This study used a mouse model of gestational HTX to evaluate ASD-like phenotypes in the offspring.Methods To induce gestational HTX, pregnant mice were treated with 2-mercapto-1-methylimidazole (MMI), a thyroid hormones synthesis inhibitor, in the tap-drinking water from embryonic days (E) 10 to E14. A separate group received MMI along with a daily subcutaneous injection of T4, while the control group received regular tap water during the entire pregnancy. Female and male offspring underwent assessments for repetitive, anxious, and social behaviors from postnatal day (P) 55 to P64. On P65, mice were euthanized for the evaluation of ASD-related inflammatory markers in blood, spleen, and specific brain regions. Additionally, the expression of glutamatergic proteins (NLGN3 and HOMER1) was analyzed in the prefrontal cortex and hippocampus.Results The HTX-offspring exhibited anxious-like behavior, a subordinate state, and impaired social interactions. Subsequently, both female and male HTX-offspring displayed elevated proinflammatory cytokines in blood, including IL-1 beta, IL-6, IL-17A, and TNF-alpha, while only males showed reduced levels of IL-10. The spleen of HTX-offspring of both sexes showed increased Th17/Treg ratio and M1-like macrophages. In the prefrontal cortex and hippocampus of male HTX-offspring, elevated levels of IL-17A and reduced IL-10 were observed, accompanied by increased expression of hippocampal NLGN3 and HOMER1. All these observations were compared to those observed in the Control-offspring. Notably, the supplementation with T4 during the MMI treatment prevents the development of the observed phenotypes. Correlation analysis revealed an association between maternal T4 levels and specific ASD-like outcomes.Discussion This study validates human observations, demonstrating for the first time that gestational HTX induces ASD-like phenotypes in the offspring, highlighting the need of monitoring thyroid function during pregnancy.

Revista



Revista ISSN
Frontiers In Endocrinology 1664-2392

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Endocrinology & Metabolism
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 González-Madrid, Enrique Hombre Universidad Nacional Andrés Bello - Chile
Pontificia Universidad Católica de Chile - Chile
2 Rangel-Ramírez, Ma Andreina - Universidad Nacional Andrés Bello - Chile
Pontificia Universidad Católica de Chile - Chile
3 OPAZO-DELGADO, MARIA CECILIA Mujer Pontificia Universidad Católica de Chile - Chile
Univ Amer - Chile
Universidad de Las Américas, Chile - Chile
4 Méndez, Luis - Universidad Nacional Andrés Bello - Chile
Pontificia Universidad Católica de Chile - Chile
5 BOHMWALD-PRIETO, KAREN Mujer Pontificia Universidad Católica de Chile - Chile
Universidad Autónoma de Chile - Chile
6 Bueno, Susan M. - Pontificia Universidad Católica de Chile - Chile
7 Gonzalez, Pablo A. - Pontificia Universidad Católica de Chile - Chile
8 KALERGIS-PARRA, ALEXIS MIKES Hombre Pontificia Universidad Católica de Chile - Chile
Facultad de Medicina - Chile
9 Riedel, Claudia A. - Universidad Nacional Andrés Bello - Chile
Pontificia Universidad Católica de Chile - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Universidad de Chile
Fondo Nacional de Desarrollo Científico y Tecnológico
Millennium Institute on Immunology and Immunotherapy (IMII)
Agencia Nacional de Investigación y Desarrollo
Agencia Nacional de Investigacin y Desarrollo10.13039/501100020884

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
We thank LM for all administrative and technical support in performing this work and the Millennium Institute on Immunology and Immunotherapy (IMII) for support.
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Millennium Institute on Immunology and Immunotherapy PROGRAMA ICM - ANID, ICN2021_045; FONDECYT #1191300, #1231905, #1231851, and #11221280. PG is supported by FONDECYT grant 1240971 and UC grant PUENTE-2023-18. EG-M thanks to ANID for providing a Ph.D. Scholarship (21202085). Acknowledgments
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Millennium Institute on Immunology and Immunotherapy PROGRAMA ICM - ANID, ICN2021_045; FONDECYT #1191300, #1231905, #1231851, and #11221280. PG is supported by FONDECYT grant 1240971 and UC grant PUENTE-2023-18. EG-M thanks to ANID for providing a Ph.D. Scholarship (21202085). Acknowledgments

Muestra la fuente de financiamiento declarada en la publicación.